Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

Deininger, Michael W.; O’Brien, Stephen G.; Ford, John M.; Druker, Brian J.

doi:10.1200/jco.2003.11.143

Cited by 356 publications

(309 citation statements)

References 25 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…21 Because imatinib effectively targets BCR-ABL, a degree of myelosuppression is expected in the early phases of treatment, before normal stem cells become predominant and normal hematopoiesis regenerates. 22 Since the 5-year analysis, routine reporting of AEs has been discontinued, with only SAE reporting ongoing. The most frequently reported SAEs in this analysis were fever, vomiting, abdominal pain and nausea, consistent with previous reports.…”

Section: Iris 6-year Follow-upmentioning

confidence: 99%

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

et al. 2009

View full text Add to dashboard Cite

Imatinib mesylate is considered standard of care for firstline treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n ¼ 553) or interferon-a (IFN) plus cytarabine (n ¼ 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88%--or 95% when only CMLrelated deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

show abstract

Section: Iris 6-year Follow-upmentioning

confidence: 99%

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

et al. 2009

View full text Add to dashboard Cite

show abstract

“…We treated PLC1 lymphoblastic lymphoma cells with imatinib, an effective inhibitor of Bcr/Abl tyrosine kinase activity (Deininger et al, 2003), and assayed CKIIa activity. As shown in Figure 5a, exposure of PLC1 cells to 5 mM STI-571 significantly inhibited Bcr/Abl P190, as measured by the marked reduction in the level of tyrosine-phosphorylated proteins detected in these cells.…”

Section: Ckiia Forms a Complex With P210 And P190 Bcr/ablmentioning

confidence: 99%

Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

et al. 2003

View full text Add to dashboard Cite

“…Imatinib has rather rare serious adverse events in cancer patients, but mild to moderate adverse events are common. Imatinib mediated edema is frequent, affecting more than 50% of patients (17). Often edema is periorbital in presentation with peripheral edema also occurring.…”

Section: Inhibition Of Tyrosine Kinasesmentioning

confidence: 99%

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials

Iwamoto

Distler

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

Efficient antifibrotic therapies are not available for patients with systemic sclerosis (SSc). This review summarizes the current preclinical and clinical evidence for imatinib and related tyrosine kinase inhibitors as potential antifibrotic therapies for SSc and other fibrotic diseases. In experimental models of SSc, imatinib, nilotinib, and dasatinib demonstrated strong antifibrotic effects. Imatinib not only prevented fibrosis in the bleomycin-induced model of dermal fibrosis and the tight skin mouse-1 model but also reduced established fibrosis in a modified bleomycin model. Open-label, proof-of-concept trials in SSc showed moderate effects on skin fibrosis, biological measures of skin fibrosis, and lung fibrosis compared with baseline measures. However, whether this reflects the natural course of the disease or is a result of treatment effects is unclear and needs to be analyzed in larger, multicenter, randomized, placebo-controlled trials. Toxicity is expected from cancer trials with frequent mild to moderate adverse events. This review summarizes the current preclinical and clinical evidence for imatinib and related tyrosine kinase inhibitors as potential anti-fibrotic therapies in SSc and other fibrotic diseases. Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials

show abstract

Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib

Cited by 356 publications

References 25 publications

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials

Contact Info

Product

Resources

About